-+ 0.00%
-+ 0.00%
-+ 0.00%

Jiangxi Biology (06915): Veterinary tetanus antitoxin production line officially put into operation

Zhitongcaijing·07/27/2026 00:17:02
Listen to the news

According to the Zhitong Finance App, Jiangxi Biotech (06915) announced that the company's wholly-owned subsidiary Chifeng Born Pharmaceutical Co., Ltd. (Chifeng Bonen) veterinary tetanus antitoxin (veterinary TAT) production line was officially put into operation on July 20, 2026 in Chifeng City, Inner Mongolia Autonomous Region.

Veterinary TAT is mainly used to prevent and treat animal tetanus caused by trauma or surgery. Tetanus is a fatal infectious disease caused by a toxin produced by Clostridium tetanus that acts on the nervous system of animals. Veterinary TAT provides passive immune protection to animals by neutralizing tetanus toxins.

The board of directors believes that this commissioning marks key progress in the Group's “human drug+veterinary medicine” two-wheel drive strategy, expanding the Group's antiserum product layout from the human field to the animal health field, providing production capacity guarantees for large-scale production and commercialization of veterinary antiserum products, effectively enriching the Group's multi-category portfolio of antiserum products, and strengthening business growth momentum.